The9 Q2 Results: EPS $0.01, sales $712,000

0 min read | Published on 24 Aug 2026, 07:56 PM |Updated on 24 Aug 2026, 07:56 PM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

The9 reported quarterly EPS of $0.01
Sales for the quarter stood at $712,000
No prior-period comparisons were disclosed

*this image is generated using AI for illustrative purposes only.

The9 (NASDAQ: NCTY) reported quarterly earnings of $0.01 per share. The company recorded $712,000 in sales for the period.

Financial Overview

The filing discloses basic top-line and bottom-line figures without comparative data from prior periods.

Metric	Value
Earnings Per Share	$0.01
Sales	$712,000

No analyst estimates, margin details, or balance sheet items were provided in the source text.

How does The9's current revenue of $712,000 compare to the same quarter in the previous year, and what does this indicate about its growth trajectory?

What specific operational changes or strategic initiatives contributed to the company achieving a positive EPS of $0.01 despite relatively low sales volume?

Are there any upcoming product launches or partnerships that could significantly drive revenue growth in the next fiscal quarter?

The9 investee Nanyang Biologics clears vote for Nasdaq listing

1 min read | Published on 21 Aug 2026, 06:11 PM |Updated on 21 Aug 2026, 06:16 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

RF Acquisition Corp II shareholders approved the business combination with Nanyang Biologics on August 19, 2026
The9 expects to hold approximately 15% to 16% of the combined Nasdaq-listed company
Nanyang Biologics plans to trade under the ticker symbol "NYB"
The transaction remains subject to customary closing conditions

*this image is generated using AI for illustrative purposes only.

Nanyang Biologics Pte. Ltd. advanced toward its planned Nasdaq listing after shareholders of RF Acquisition Corp II approved the proposed business combination on August 19, 2026.

The vote marks a key milestone for the Singapore-based AI-driven drug discovery firm, which plans to trade under the reserved ticker symbol "NYB." The transaction remains subject to customary closing conditions.

Strategic Stake for The9

The9 Limited (NASDAQ: NCTY) holds a strategic equity stake in Nanyang Biologics through its wholly owned subsidiary, Gamenow.net (Hong Kong) Limited. Upon completion of the business combination, The9 is expected to hold approximately 15% to 16% of the combined, Nasdaq-listed company.

This investment aligns with The9’s strategy of extending into promising AI-driven opportunities beyond its core gaming ecosystem, the9bit.

Business Profile

Nanyang Biologics specializes in applying artificial intelligence to discover novel drug candidates from natural compounds. Its Vecura™ AI platform leverages a proprietary library of more than one million natural compounds to identify promising bioactive candidates and mechanisms often overlooked by conventional synthetic-first approaches.

George Lai, Chief Executive Officer of The9, stated that the vote reflects strong shareholder confidence in Nanyang Biologics’ business. He noted that the progress reinforces the value of The9’s investment and widens possibilities as the company builds its presence across the AI sector.

How might Nanyang Biologics' reliance on natural compounds differentiate its pipeline valuation compared to traditional synthetic drug developers on the Nasdaq?

What specific synergies or cross-promotional opportunities could emerge between The9's 9bit gaming ecosystem and Nanyang Biologics' AI platform?

Given the current regulatory scrutiny on SPAC mergers, what are the primary risks that could delay or prevent the final closing of this business combination?